Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$530M |
| 2 |
AbbVie
ABBV
|
+$429M |
| 3 |
Boston Scientific
BSX
|
+$292M |
| 4 |
Snap
SNAP
|
+$241M |
| 5 |
Royalty Pharma
RPRX
|
+$223M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$327M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$295M |
| 3 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$294M |
| 4 |
Sysco
SYY
|
+$209M |
| 5 |
Shopify
SHOP
|
+$176M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.65% |
| 2 | Healthcare | 19.7% |
| 3 | Consumer Discretionary | 10.81% |
| 4 | Financials | 9.9% |
| 5 | Communication Services | 8.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Coca-Cola
KO
$361B
| $230M | 0.13% |
5,139,971
-322,215
| -6% | -$14.8M |
|
177
Uber
UBER
$139B
| $224M | 0.13% |
7,200,625
-2,476,686
| -26% | -$77.2M |
|
178
Bio-Techne
TECH
$11.2B
| $222M | 0.12% |
3,369,348
-30,732
| -0.9% | -$1.84M |
|
179
Marvell Technology
MRVL
$170B
| $222M | 0.12% |
6,338,089
-1,406,022
| -18% | -$41.2M |
|
|
180
Royalty Pharma
RPRX
$26.1B
| $219M | 0.12% |
+4,507,138
| New | +$223M |
|
|
MRSH
181
Marsh
MRSH
$87.7B
| $216M | 0.12% |
2,009,141
+286,367
| +17% | +$29M |
|
182
Citigroup
C
$222B
| $215M | 0.12% |
4,215,134
+835,174
| +25% | +$39.6M |
|
183
Verizon
VZ
$198B
| $212M | 0.12% |
3,842,533
-1,097,620
| -22% | -$61.7M |
|
|
GWPH
184
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $211M | 0.12% |
1,721,317
+965
| +0.1% | +$109K |
|
185
US Bancorp
USB
$98.9B
| $210M | 0.12% |
5,704,724
-1,361,355
| -19% | -$48.5M |
|
186
Sensient Technologies
SXT
$5.3B
| $210M | 0.12% |
4,016,851
+17,200
| +0.4% | +$814K |
|
187
Elevance Health
ELV
$82B
| $207M | 0.12% |
788,846
+161,372
| +26% | +$43.1M |
|
188
Stryker
SYK
$129B
| $207M | 0.12% |
1,146,424
+606,361
| +112% | +$112M |
|
189
S&P Global
SPGI
$130B
| $202M | 0.11% |
614,631
+74,454
| +14% | +$22.4M |
|
190
TSMC
TSM
$2.07T
| $201M | 0.11% |
3,542,974
-169,698
| -5% | -$8.94M |
|
|
MGP
191
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $199M | 0.11% |
7,331,679
+62,956
| +0.9% | +$1.62M |
|
192
Lowe's Companies
LOW
$119B
| $198M | 0.11% |
1,462,722
-130,837
| -8% | -$14.9M |
|
193
Waste Management
WM
$95.7B
| $197M | 0.11% |
1,862,765
-1,318,153
| -41% | -$133M |
|
194
Integra LifeSciences
IART
$1.52B
| $197M | 0.11% |
4,195,186
-110,740
| -3% | -$5.44M |
|
195
BioMarin Pharmaceuticals
BMRN
$11.7B
| $197M | 0.11% |
1,595,961
+463,882
| +41% | +$46.1M |
|
196
Vulcan Materials
VMC
$37B
| $196M | 0.11% |
1,689,789
-990,280
| -37% | -$108M |
|
197
Ryanair
RYAAY
$29.9B
| $194M | 0.11% |
7,295,530
-55,643
| -0.8% | -$1.41M |
|
|
PRAH
198
DELISTED
PRA Health Sciences, Inc.
PRAH
| $193M | 0.11% |
1,982,228
+22,452
| +1% | +$2.09M |
|
199
Take-Two Interactive
TTWO
$45B
| $191M | 0.11% |
1,370,850
+329,083
| +32% | +$43M |
|
200
Clorox
CLX
$11.8B
| $190M | 0.11% |
864,331
+121,844
| +16% | +$24.3M |
|
Similar funds
Janus Henderson Group's Q2 2020 Portfolio in Review
As of Q2 2020, Janus Henderson Group held 1,423 positions worth $178B, up 23% from $145B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Janus Henderson Group's Q2 2020 filing shows 132 new, 511 increased, 643 reduced and 125 closed positions. Its largest new stake was Royalty Pharma: 4,507,138 shares worth $219M. The largest sale was Boeing, an estimated $327M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2020 buy was Royalty Pharma: 4,507,138 shares worth $219M.
- Janus Henderson Group added most to T-Mobile US in Q2 2020, an estimated $530M increase.
- Janus Henderson Group's biggest Q2 2020 reduction was Boeing, cutting an estimated $327M.
- Janus Henderson Group fully exited Allergan plc in Q2 2020, selling an estimated $128M.
- Janus Henderson Group's ten largest holdings make up 23% of its $178B portfolio in Q2 2020.
- Janus Henderson Group opened 132 new positions and closed 125 in Q2 2020.
- Janus Henderson Group's portfolio value rose 23% quarter-over-quarter to $178B.
Based on Janus Henderson Group's 13F filing for Q2 2020, filed 14 Aug 2020.